169 related articles for article (PubMed ID: 22407918)
1. Enhancing immunostimulatory function of human embryonic stem cell-derived dendritic cells by CD1d overexpression.
Zeng J; Shahbazi M; Wu C; Toh HC; Wang S
J Immunol; 2012 May; 188(9):4297-304. PubMed ID: 22407918
[TBL] [Abstract][Full Text] [Related]
2. Human dendritic cells derived from embryonic stem cells stably modified with CD1d efficiently stimulate antitumor invariant natural killer T cell response.
Zeng J; Wang S
Stem Cells Transl Med; 2014 Jan; 3(1):69-80. PubMed ID: 24292792
[TBL] [Abstract][Full Text] [Related]
3. Dendritic cell internalization of α-galactosylceramide from CD8 T cells induces potent antitumor CD8 T-cell responses.
Choi DH; Kim KS; Yang SH; Chung DH; Song B; Sprent J; Cho JH; Sung YC
Cancer Res; 2011 Dec; 71(24):7442-51. PubMed ID: 22028323
[TBL] [Abstract][Full Text] [Related]
4. Olea europaea pollen lipids activate invariant natural killer T cells by upregulating CD1d expression on dendritic cells.
Abós-Gracia B; del Moral MG; López-Relaño J; Viana-Huete V; Castro L; Villalba M; Martínez-Naves E
J Allergy Clin Immunol; 2013 May; 131(5):1393-9.e5. PubMed ID: 23265858
[TBL] [Abstract][Full Text] [Related]
5. Multiple antigen-targeted immunotherapy with alpha-galactosylceramide-loaded and genetically engineered dendritic cells derived from embryonic stem cells.
Fukushima S; Hirata S; Motomura Y; Fukuma D; Matsunaga Y; Ikuta Y; Ikeda T; Kageshita T; Ihn H; Nishimura Y; Senju S
J Immunother; 2009 Apr; 32(3):219-31. PubMed ID: 19242378
[TBL] [Abstract][Full Text] [Related]
6. Modification of human embryonic stem cell-derived dendritic cells with mRNA for efficient antigen presentation and enhanced potency.
Nishimoto KP; Tseng SY; Lebkowski JS; Reddy A
Regen Med; 2011 May; 6(3):303-18. PubMed ID: 21548736
[TBL] [Abstract][Full Text] [Related]
7. Exploiting the CD1d-iNKT cell axis for potentiation of DC-based cancer vaccines.
Lameris R; Schneiders FL; de Gruijl TD; van der Vliet HJ
Methods Mol Biol; 2014; 1139():155-65. PubMed ID: 24619678
[TBL] [Abstract][Full Text] [Related]
8. Sulfatide inhibits α-galactosylceramide presentation by dendritic cells.
Kanamori M; Tasumi Y; Iyoda T; Ushida M; Inaba K
Int Immunol; 2012 Feb; 24(2):129-36. PubMed ID: 22247226
[TBL] [Abstract][Full Text] [Related]
9. On/off TLR signaling decides proinflammatory or tolerogenic dendritic cell maturation upon CD1d-mediated interaction with invariant NKT cells.
Caielli S; Conforti-Andreoni C; Di Pietro C; Usuelli V; Badami E; Malosio ML; Falcone M
J Immunol; 2010 Dec; 185(12):7317-29. PubMed ID: 21078913
[TBL] [Abstract][Full Text] [Related]
10. Administration of alpha-galactosylceramide impairs the survival of dendritic cell subpopulations in vivo.
Simkins HM; Hyde E; Farrand KJ; Ong ML; Degli-Esposti MA; Hermans IF; Ronchese F
J Leukoc Biol; 2011 May; 89(5):753-62. PubMed ID: 21297009
[TBL] [Abstract][Full Text] [Related]
11. Vaccination with antigen-transfected, NKT cell ligand-loaded, human cells elicits robust in situ immune responses by dendritic cells.
Shimizu K; Mizuno T; Shinga J; Asakura M; Kakimi K; Ishii Y; Masuda K; Maeda T; Sugahara H; Sato Y; Matsushita H; Nishida K; Hanada K; Dorrie J; Schaft N; Bickham K; Koike H; Ando T; Nagai R; Fujii S
Cancer Res; 2013 Jan; 73(1):62-73. PubMed ID: 23108144
[TBL] [Abstract][Full Text] [Related]
12. Uncoupling between CD1d upregulation induced by retinoic acid and conduritol-B-epoxide and iNKT cell responsiveness.
Balreira A; Cavallari M; Sá Miranda MC; Arosa FA
Immunobiology; 2010 Jun; 215(6):505-13. PubMed ID: 19651460
[TBL] [Abstract][Full Text] [Related]
13. Activation of human invariant natural killer T cells with a thioglycoside analogue of α-galactosylceramide.
Hogan AE; O'Reilly V; Dunne MR; Dere RT; Zeng SG; O'Brien C; Amu S; Fallon PG; Exley MA; O'Farrelly C; Zhu X; Doherty DG
Clin Immunol; 2011 Aug; 140(2):196-207. PubMed ID: 21493160
[TBL] [Abstract][Full Text] [Related]
14. Functional education of invariant NKT cells by dendritic cell tuning of SHP-1.
Napolitano A; Pittoni P; Beaudoin L; Lehuen A; Voehringer D; MacDonald HR; Dellabona P; Casorati G
J Immunol; 2013 Apr; 190(7):3299-308. PubMed ID: 23427253
[TBL] [Abstract][Full Text] [Related]
15. Innate Valpha14(+) natural killer T cells mature dendritic cells, leading to strong adaptive immunity.
Fujii S; Shimizu K; Hemmi H; Steinman RM
Immunol Rev; 2007 Dec; 220():183-98. PubMed ID: 17979847
[TBL] [Abstract][Full Text] [Related]
16. Invariant NKT cells preferentially modulate the function of CD8 alpha+ dendritic cell subset in inducing type 1 immunity against infection.
Joyee AG; Uzonna J; Yang X
J Immunol; 2010 Feb; 184(4):2095-106. PubMed ID: 20089704
[TBL] [Abstract][Full Text] [Related]
17. Decreased expressions of CD1d molecule on liver dendritic cells in subcutaneous tumor bearing mice.
Tatsumi T; Takehara T; Yamaguchi S; Sasakawa A; Yamamoto M; Fujita Y; Miyagi T; Ohkawa K; Hayashi N
J Hepatol; 2008 Nov; 49(5):779-86. PubMed ID: 18760855
[TBL] [Abstract][Full Text] [Related]
18. Differentiation of human embryonic stem cells into immunostimulatory dendritic cells under feeder-free culture conditions.
Su Z; Frye C; Bae KM; Kelley V; Vieweg J
Clin Cancer Res; 2008 Oct; 14(19):6207-17. PubMed ID: 18829500
[TBL] [Abstract][Full Text] [Related]
19. Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients.
Bonehill A; Van Nuffel AM; Corthals J; Tuyaerts S; Heirman C; François V; Colau D; van der Bruggen P; Neyns B; Thielemans K
Clin Cancer Res; 2009 May; 15(10):3366-75. PubMed ID: 19417017
[TBL] [Abstract][Full Text] [Related]
20. Cancer immunotherapy using artificial adjuvant vector cells to deliver NY-ESO-1 antigen to dendritic cells in situ.
Fujii SI; Yamasaki S; Hanada K; Ueda S; Kawamura M; Shimizu K
Cancer Sci; 2022 Mar; 113(3):864-874. PubMed ID: 34971473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
